SEC Form 4 · accession 0001104659-18-002674
Adaptimmune Therapeutics PLC · ADAP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rafael Amado
Officer — Chief Medical Officer
Period of report
Jan 12, 2018
Accepted (ET)
Jan 17, 2018 · 5:20 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621227
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to purchase Ordinary SharesF1,F2 | $1.30 | Jan 12, 2018 | A | 859,968 | A | — | Jan 12, 2028 | Ordinary Shares | 859,968 | 859,968 | D |
| Option to purchase Ordinary SharesF3,F4,F5 | $0.0014 | Jan 12, 2018 | A | 192,060 | A | — | — | Ordinary Shares | 192,060 | 192,060 | D |
Explanation of responses
- F1The exercise price was converted from GBP0.96 based on an exchange rate of $U.S. 1.3542 - GBP1.00. The actual exercise price will be the pounds sterling amount.
- F2Exercisable as to 214,992 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in monthly installments of 17,916 Ordinary Shares on the twelfth of each month from February 12, 2019 through January 12, 2022.
- F3The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.3542 - GBP1.00. The actual exercise price will be the pounds sterling amount.
- F4Exercisable as to 48,015 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in annual installments of 48,015 Ordinary Shares on the twelfth of each January from January 12, 2020 through January 12, 2022.
- F5The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.